Athira Pharma Report issue

For profit Phase 1 Phase 2
Founded: Seattle WA United States (2011)

Organization Overview

First Clinical Trial
2017
NCT03298672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Athira Pharma | M3 | M3 Biotechnology, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ath-1017 (6 trials)

Drugs in Phase 1 Trials (1)

ath-1020 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Dementia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2